drugset / Trial / NCT02453555

Empagliflozin Add on to Linagliptin Study in Japanese Patient With Type 2 Diabetes Mellitus

NCT02453555

Phase 3 Completed 275 enrolled Boehringer Ingelheim Eli Lilly and Company · collab
RandomizedParallel-groupDouble-blindTreatment

Summary

This trial will compare the use of fixed dose combination of empagliflozin and linagliptin to linagliptin alone in patient with type 2 diabetes mellitus

Timeline

Start
2015-05-14
Primary completion
2016-08-26
Completion
2017-03-27

Drugs

EvaluationDrugModalityDoseRoute
Subject Empagliflozin Small molecule 10 mg
Subject Empagliflozin Small molecule 25 mg
Comparator Linagliptin Small molecule 5 mg